

# **THE BURDEN OF MUSCULOSKELETAL CONDITIONS AT THE START OF THE NEW MILLENNIUM**

Report of a  
WHO Scientific Group



World Health Organization

Geneva

*This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization*

**WHO Technical Report Series**

**919**

# **THE BURDEN OF MUSCULOSKELETAL CONDITIONS AT THE START OF THE NEW MILLENNIUM**

Report of a  
WHO Scientific Group



**World Health Organization**

**Geneva 2003**

WHO Library Cataloguing-in-Publication Data

WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. (2003 : Geneva, Switzerland).

The burden of musculoskeletal conditions at the start of the new millennium : report of a WHO scientific group.

(WHO technical report series ; 919)

1.Musculoskeletal diseases — epidemiology 2.Musculoskeletal diseases — classification  
3.Health status indicators 4.Cost of illness 5.Quality of Life 6.Disability evaluation  
I.Title II.Series

ISBN 92 4 120919 4  
ISSN 0512-3054

(NLM classification: WE 15)

**© World Health Organization 2003**

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 2476; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to Publications, at the above address (fax: +41 22 791 4806; e-mail: [permissions@who.int](mailto:permissions@who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Of the experts who participated in this Consultation, five experts (i.e. Professor P. Brooks, Professor M.C. Hochberg, Professor P. Lips, Professor R. Rizzoli and Professor G. Stucki) declared an interest in the subject matter considered. These interests ranged from consultancies for, the receipt of research support from, share holding in, and speaking at conferences sponsored by companies which manufacture or have another interest in products for musculoskeletal conditions. The Consultation did not, however, discuss any such products, either directly by brand name or indirectly by reference to generic products.

**Typeset in Hong Kong  
Printed in Singapore**

# WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium

Geneva, 13–15 January 2000

## Members

Dr J. Agel, Department of Orthopaedics, University of Minnesota, Minneapolis, MN, USA

Dr K. Akesson, Department of Orthopaedic Surgery, Malmö University Hospital, Malmö, Sweden (*Joint Vice-Chairman*)

Dr P.C. Amadio, Mayo Clinic, Rochester, MN, USA

Mrs M. Anderson, International Osteoporosis Foundation, Hofstetten, Switzerland

Dr E. Badley, Director, Arthritis Community Research and Evaluation Unit, University Health Network (Princess Margaret Hospital), Toronto, Ontario, Canada

Dr G. Balint, Head of Rheumatology Department, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary

Professor N. Bellamy, Director, Center of National Research on Disability & Rehabilitation Medicine, Department of Medicine, Royal Brisbane Hospital, Brisbane, Queensland, Australia

Dr S. Bigos, Department of Orthopedics, University of Washington, Seattle, WA, USA

Professor N. Bishop, Sheffield Children's Hospital, Sheffield, England

Mr B. Bivans, Coordinator, Global Road Safety Partnership, International Federation of Red Cross and Red Crescent Societies, Geneva, Switzerland

Mr P.A. Bjorke, Arthritis and Rheumatism International, Norwegian Rheumatism Association, Oslo, Norway

Professor P. Brooks, Executive Dean of Health Sciences, University of Queensland, Brisbane, Queensland, Australia

Professor B.D. Browner, Department of Orthopedic Surgery, University of Connecticut Health Center, Farmington, CT, USA

Dr J. Buckwalter, University of Iowa Hospitals, Department of Orthopedics, Iowa City, IA, USA

Dr L. Callahan, Research Member, Thurston Arthritis Research Centre, University of Carolina, Chapel Hill, NC, USA

Professor W.H. Chahade, Director, Rheumatology Department, Hospital do Servidor Publico, São Paulo, Brazil

Dr A. Chopra, Pune, India

Professor M. Cimmino, Department of Internal Medicine, General Medicine and Therapy Clinic, University of Genoa, Genoa, Italy (*Joint Rapporteur*)

Professor C. Cooper, Medical Research Council, Environmental Epidemiology Unit, Southampton General Hospital, Southampton, England

Dr J. Darmawan, Seroja Rheumatic Center, Semarang, Indonesia

- Dr K.C. de Mesquita, Panema, Rio de Janeiro, Brazil
- Dr M. De Smedt, Head of Health and Safety Statistics, European Commission, Luxembourg
- Professor P. Delmas, Research Unit, Institut National de la Santé et de la Recherche Médicale, Lyon, France
- Professor J. Dequeker, Catholic University of Louvain, Louvain, Belgium
- Professor P. Dieppe, Health Services Research Collaboration, University of Bristol, Bristol, England (*Joint Rapporteur*)
- Professor M. Dougados, Department of Rheumatology, Cochin Hospital, Paris, France
- Dr K.E. Dreinhofer, Department of Orthopaedics, Ulm University, Ulm, Germany
- Dr G.E. Ehrlich, Adjunct Professor of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
- Dr B.M. Gans, New York, NY, USA
- Professor H.K. Genant, Executive Director, Osteoporosis and Arthritis Research Group, University of California, San Francisco, CA, USA
- Dr D. Grob, Schulthess Clinic, Zurich, Switzerland
- Professor F. Guillemin, School of Public Health, Vandoeuvre-les-Nancy, France
- Dr K. Hamelynck, Department of Orthopaedics, Slotervaart Hospital, Amsterdam, Netherlands
- Dr E. Hazan, Attending Surgeon and Chief of Orthopaedic Traumatology Service, National Institute of Orthopaedics, Mexico City, Mexico
- Professor J.M. Hazes, Department of Rheumatology, University Hospital of Rotterdam, Rotterdam, Netherlands (*Joint Vice-Chairman*)
- Professor M.C. Hochberg, Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, USA
- Professor O. Johnell, Professor of Orthopaedics, Department of Orthopaedic Surgery, Malmö University Hospital, Malmö, Sweden
- Professor J. Kanis, Centre for Metabolic Bone Diseases at Sheffield, Sheffield, England
- Dr A.D. Kinasha, Head of Neurosurgery, Muhimbili Orthopaedic Institute, Dar es Salaam, United Republic of Tanzania
- Mr A.U. Kuder, Kuder, Smollar & Friedman, Washington, DC, USA
- Professor E.M.C. Lau, Department of Community and Family Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China
- Dr R.C. Lawrence, Epidemiology/Data Systems Program Officer, National Institute of Arthritis and Musculoskeletal and Skin Diseases/National Institutes of Health, Bethesda, MD, USA
- Professor L. Lidgren, Department of Orthopaedics, University Hospital, Lund, Sweden

- Professor P. Lips, Department of Endocrinology, Academic Hospital, Vrije University, Amsterdam, Netherlands (*Joint Rapporteur*)
- Professor S. Lohmander, Department of Orthopaedics, University Hospital, Lund, Sweden
- Mr S. Luchter, Department of Transportation Administrator, National Highway Traffic Safety Administration, Washington, DC, USA
- Dr E.J. Mackenzie, Center for Injury Research and Policy, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD, USA (*Joint Rapporteur*)
- Dr J.C. Marini, Head, Heritable Disorders Branch, National Institutes of Health, Bethesda, MD, USA
- Professor J. Melton, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
- Dr A. Mithal, Senior Consultant Endocrinologist, Indraprastha Apollo Hospitals, New Delhi, India
- Dr C. Mock, Assistant Professor, Department of Surgery, Harborview Medical Centre, Seattle, WA, USA
- Professor D. Mohan, Coordinator, Transportation Research and Injury Prevention Programme, Indian Institute of Technology, New Delhi, India
- Dr R. Moser, Association for the Study of Internal Fixation (AO), Clinical Investigation and Documentation, Davos, Switzerland
- Professor V.A. Nassonova, Director of Institute of Rheumatology, Russian Academy of Medical Sciences, Moscow, Russian Federation
- Professor M. Nordin, Director, Occupational and Industrial Orthopedic Center, Hospital for Joint Diseases Orthopedic Institute, School of Medicine, New York University, New York, NY, USA
- Professor H.-J. Oestern, Klinik für Unfall- und Wiederstellungschirurgie, Allgemeines Krankenhaus, Celle, Germany
- Ms D. Pattison, Bone and Joint Monitor Project, Duke of Cornwall Rheumatology Department, Royal Cornwall Hospital, Truro, England
- Professor R.E. Petty, Department of Pediatrics, British Columbia's Children's Hospital, Vancouver, British Columbia, Canada
- Dr G. Poor, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary
- Professor J.J.H. Rasker, Department of Rheumatology and Communication Studies, University of Twente, Enschede, Netherlands
- Professor H. Raspe, Institute for Social Medicine, Medical University, Lübeck, Germany
- Professor J.Y. Reginster, Bone Cartilage Unit, University of Liège, Liège, Belgium
- Professor R. Rizzoli, Division of Bone Disease, Department of Internal Medicine, Cantonal Hospital, Geneva, Switzerland
- Dr D. Sethi, Health Policy Unit, London School of Hygiene and Tropical Medicine, London, England

Dr T.K. Shanmugasundaram, President, World Orthopaedic Concern, Madras, India

Dr C.M. Shewan, Director, Research and Scientific Affairs for the American Academy of Orthopedic Surgeons, Rosemont, IL, USA

Dr K. Shichikawa, Yukioka Hospital, Osaka, Japan

Professor G. Stucki, Department of Physical Medicine and Rehabilitation, Ludwig Maximilians University, Munich, Germany

Professor D. Symmons, Arthritis Research Council, Epidemiology Research Unit, University of Manchester, Manchester, England

Professor S. van der Linden, Department of Rheumatology, Academic Hospital of Maastricht, Maastricht, Netherlands

Professor T.L. Vischer, Division of Rheumatology, Cantonal University Hospital, Geneva, Switzerland

Professor N.E. Walsh, Department of Rehabilitation Medicine, University of Texas Health Science Centre at San Antonio, San Antonio, TX, USA (*Joint Rapporteur*)

Professor S.L. Weinstein, University of Iowa Hospitals, Iowa City, IA, USA

Professor A.D. Woolf, Consultant Rheumatologist, Duke of Cornwall Rheumatology Department, Royal Cornwall Hospital, Truro, England (*Chairman*)

Professor E. Yelin, Arthritis Research Group, University of California, San Francisco, CA, USA

Professor H. Yoshizawa, Fujita Health, University School of Medicine, Tokyo City, Japan

### **Secretariat**

Dr N. Khaltayev, Coordinator, Chronic Respiratory Diseases and Arthritis, Management of Noncommunicable Diseases, WHO, Geneva, Switzerland (*Secretary*)



# Contents

1. Introduction	1
1.1 Introduction by the Director-General	1
1.2 Scope and aims	3
2. Global burden of disease	6
2.1 The Global Burden of Disease Study	6
2.1.1 Summary measures of population health	8
2.1.2 Health states	9
2.2 Estimating the global burden of musculoskeletal conditions	11
2.3 Methodology of estimating the burden of disease	16
3. Incidence and prevalence of musculoskeletal conditions	19
3.1 Introduction	19
3.1.1 Potential further sources of data	20
3.1.2 Recommendations for making estimates of incidence and prevalence of musculoskeletal conditions	21
3.2 Rheumatoid arthritis	21
3.2.1 Definition	21
3.2.2 Incidence	23
3.2.3 Prevalence	23
3.2.4 Potential sources of further data	23
3.2.5 Recommendations for making estimates of incidence and prevalence rates of the global burden	23
3.3 Osteoarthritis	24
3.3.1 Definition	24
3.3.2 Incidence	25
3.3.3 Prevalence	25
3.3.4 Potential sources of further data	26
3.3.5 Recommendations for making estimates of incidence and prevalence rates of the global burden	27
3.4 Osteoporosis	27
3.4.1 Definition	27
3.4.2 Incidence	30
3.4.3 Prevalence	33
3.4.4 Potential sources of further data	36
3.4.5 Recommendations for making estimates of incidence and prevalence rates of the global burden	36
3.5 Spinal disorders	37
3.5.1 Definition	37
3.5.2 Incidence	41
3.5.3 Prevalence	43
3.5.4 Potential sources of further data	44
3.5.5 Recommendations for making estimates of incidence and prevalence rates of the global burden	44
3.6 Severe limb trauma	44
3.6.1 Definition	44
3.6.2 Incidence	45
3.6.3 Prevalence	48



3.6.4	Potential sources of further data	48
3.6.5	Recommendations for making estimates of incidence and prevalence rates of the global burden	49
4.	<b>Severity and course of the conditions</b>	50
4.1	Introduction	50
4.2	Rheumatoid arthritis	52
4.2.1	Model of the condition	52
4.2.2	How has loss of health been described and quantified?	54
4.2.3	What is the role of geographical and socioeconomic factors?	55
4.3	Osteoarthritis	55
4.3.1	Model of the condition	55
4.3.2	How has loss of health been described and quantified?	56
4.3.3	What is the role of geographical and socioeconomic factors?	57
4.4	Osteoporosis	57
4.4.1	Model of the condition	57
4.4.2	How has loss of health been described and quantified?	59
4.4.3	What is the role of geographical and socioeconomic factors?	59
4.5	Spinal disorders	60
4.5.1	Model of the conditions	60
4.5.2	How has the loss of health been described and quantified?	64
4.5.3	What is the role of geographical and socioeconomic factors?	65
4.5.4	Spinal pain and disability	65
4.6	Severe limb trauma	66
4.6.1	Model of the conditions	66
4.6.2	How has loss of health been described and quantified?	68
4.6.3	Role of geographical and socioeconomic factors	70
5.	<b>Health and economic indicators</b>	71
5.1	The need for health indicators	71
5.2	What should be measured by indicators for musculoskeletal conditions?	75
5.2.1	General indicators	75
5.2.2	Risk factors	76
5.2.3	Specific interventions and treatments	76
5.2.4	Consequences of musculoskeletal conditions for the individual and society	76
5.2.5	Choice of indicators	78
5.3	Economic indicators	78
5.4	Summary	85
6.	<b>Measuring the health impact and economic burden of musculoskeletal conditions on the population</b>	85
6.1	Introduction	85
6.2	Rheumatoid arthritis	92
6.2.1	Health indicators	92
6.2.2	Economic indicators	94

6.3	Osteoarthritis	94
6.3.1	Health indicators	94
6.3.2	Economic indicators	95
6.4	Osteoporosis	96
6.4.1	Health indicators	96
6.4.2	Economic indicators	98
6.5	Spinal disorders	99
6.5.1	Health indicators	99
6.5.2	Economic indicators	102
6.6	Severe limb trauma	103
6.6.1	Health indicators	103
6.6.2	Economic indicators	108
7.	<b>Describing health status and the consequences of illness or injury for the individual</b>	109
7.1	Introduction	109
7.1.1	Uses of data collected	109
7.1.2	Multidimensional health concept	109
7.1.3	Limitations of currently available measures	112
7.1.4	Boundary between health and well-being	113
7.1.5	Need for a common language and profile to describe health	114
7.1.6	Description versus valuation of health	115
7.1.7	Next steps	116
7.2	Multidimensional approach to measuring health status for musculoskeletal conditions	117
7.3	Rheumatoid arthritis	120
7.3.1	Health domains	120
7.3.2	Possible health states	123
7.3.3	Suggested instruments for measuring selected health domains	123
7.4	Osteoarthritis	125
7.4.1	Health domains	125
7.4.2	Possible health states	125
7.4.3	Suggested instruments for measuring selected health domains	126
7.5	Osteoporosis	127
7.5.1	Health domains	127
7.5.2	Possible health states	128
7.5.3	Suggested instruments for measuring selected health domains	130
7.5.4	Issues relating to children	131
7.6	Spinal disorders	131
7.6.1	Health domains	131
7.6.2	Possible health states	133
7.6.3	Suggested instruments for measuring selected health domains	133
7.7	Severe limb trauma	133
7.7.1	Health domains	133
7.7.2	Possible health states	138
7.7.3	Suggested instruments for measuring selected health domains	140

8. Inventory of published assessment instruments for musculoskeletal conditions	142
8.1 Introduction	142
8.2 Data collected	142
8.2.1 Instrument name	142
8.2.2 Bibliographic citation	142
8.2.3 Instruments designed for or used with various populations	142
8.2.4 Disease conditions	143
8.2.5 Reliability data	143
8.2.6 Validity data	143
8.2.7 Type of indicator	143
8.2.8 Areas measured	144
8.2.9 Administration	144
8.2.10 Time to complete	144
8.2.11 Language	144
8.2.12 Copy available	144
8.3 Search methodology	144
8.3.1 Experts in musculoskeletal conditions	144
8.3.2 Existing databases	145
8.3.3 Review text	145
8.4 Selected instrument listings	145
9. Conclusions and recommendations	158
9.1 Incidence and prevalence	159
9.2 Severity and course of the conditions	160
9.2.1 Rheumatoid arthritis	160
9.2.2 Osteoarthritis	160
9.2.3 Osteoporosis	160
9.2.4 Spinal disorders	160
9.2.5 Severe limb trauma	161
9.3 Health and economic indicators	161
9.4 Measuring health impact and economic burden at the population level	162
9.5 Describing health status as a consequence of illness or injury: impact on the individual	162
9.6 Recommendations of the Scientific Group	163
Acknowledgements	164
References	165
Annex	
Estimates of incidence or prevalence of key musculoskeletal disorders considered for each WHO Region	177

## 1. Introduction

A WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium met in Geneva from 13 to 15 January 2000. The meeting was opened by Dr G. Harlem Brundtland, Director-General of the World Health Organization. The meeting, organized by WHO in collaboration with the Bone and Joint Decade, marked the launch of the Bone and Joint Decade 2000–2010.

### 1.1 Introduction by the Director-General

Dr Brundtland opened by stating that during the past century, average life expectancy had risen by nearly 20 years, an unprecedented achievement but one whose success had been very unevenly distributed as health and longevity had not been brought to all of the world's population.

The increased life expectancy recorded in recent decades, together with changes in lifestyle and diet, has led to a rise in the incidence of noncommunicable diseases, also seen in the developing countries. Noncommunicable diseases now cause nearly 40% of all deaths in developing countries, affecting people of a younger age than they do in industrialized countries. The epidemiological transition, with its double burden of infectious and noncommunicable diseases, means that many developing countries now struggle with a range and volume of disease for which they are not prepared.

Dr Brundtland discussed non-fatal outcomes, mentioning that although the diseases that kill attract much of the public's attention, musculoskeletal or rheumatic diseases are the major cause of morbidity throughout the world, having a substantial influence on health and quality of life, and inflicting an enormous burden of cost on health systems. She pointed out that rheumatic diseases include more than 150 different conditions and syndromes with the common denominators of pain and inflammation. Examples of the burden include:

- 40% of people over the age of 70 years suffer from osteoarthritis of the knee.
- 80% of patients with osteoarthritis have some degree of limitation of movement, and 25% cannot perform their major daily activities of life.
- Rheumatoid arthritis, within a decade of its onset, leads to work disability, defined as a total cessation of employment in between 51% and 59% of patients.
- Low back pain has reached epidemic proportions, being reported by about 80% of people at some time in their life.

- An estimated 1.7 million hip fractures occurred worldwide in 1990, the figure being expected to exceed 6 million by 2050. Osteoporotic hip fractures account for a large proportion of the morbidity, mortality and cost of the disease.

Dr Brundtland stated further that surveys involving several developing countries have provided valuable information on the magnitude of the problem, showing that the burden of rheumatic diseases is practically equal to that encountered in the industrialized world. She summarized the history of WHO activity in the area, which had its origins at the 1976 World Health Assembly when then Director-General Halfdan Mahler said: "Perhaps the most fundamental difficulty in regard to rheumatic diseases is that the problem is insufficiently appreciated and understood. Critical to this lack of appreciation is an information deficit." Since then, a community-oriented programme for the control of rheumatic diseases has been jointly initiated by WHO and the International League of Associations for Rheumatology.

In 1989, the WHO Scientific Group on Rheumatic Diseases undertook a state-of-the-art review of a very wide spectrum of conditions, from nonspecific aches and pains in joints to full-blown rheumatoid arthritis. The review provided evidence that rheumatic diseases cause more pain and disability than any other group of conditions in developed countries, and the same pattern of morbidity is now being seen in the developing world.

Dr Brundtland referred to a 1994 Study Group that increased understanding of the factors underlying the metabolic changes and considered possible ways of preventing osteoporosis and improving treatment (1). Surveys undertaken in developed countries indicated that, by the age of 70 years, more than one in four women had sustained at least one osteoporotic fracture, and the estimated lifetime risk for wrist, hip and vertebral fractures was estimated to be 15%, very close to that of ischaemic heart disease. Further, available data leave little doubt that osteoporosis is reaching epidemic proportions and that it will become increasingly important in most countries as a result of a proportionate increase of the elderly population, as well as a notable change in risk factors.

In implementing the recommendations of this Study Group, WHO has established a task force to draw up a strategy for osteoporosis management and prevention. The International Osteoporosis Education Project aims to improve the diagnosis and care of osteoporotic patients throughout the world, with special emphasis on developing countries.

WHO envisions a way of improving community health through increased collaborative efforts with governmental and nongovernmental organizations. The aim is to increase the capacity of community control programmes to include a wide range of measures, from professional training, patient and family education, and community and patient participation to the enhancement of early detection, and effective treatment and rehabilitation. Further, such programmes should also become an integral part of health services, including existing primary health care systems. An association between chronic musculoskeletal diseases, such as osteoarthritis, low back pain, osteoporosis and gout, and such risk factors as obesity, physical inactivity, stress and smoking, provides opportunities to prevent these diseases through a change in lifestyle. Chronic musculoskeletal diseases can be prevented by including them in a more comprehensive noncommunicable diseases prevention and control programme. The potential in such an approach is great, and WHO is currently developing a global strategy to achieve this.

Dr Brundtland concluded by referring to the goal of the Bone and Joint Decade 2000–2010, which is to improve the health-related quality of life for people with musculoskeletal conditions throughout the world. She hoped that the WHO Scientific Group meeting would build on the foundations of combined efforts and expressed confidence that the outcome would not only be of great value to rheumatologists, physicians and health care workers throughout the world, but would also lead to action to bring relief and hope to the millions who suffer from musculoskeletal conditions.

## 1.2 Scope and aims

The goal of the Bone and Joint Decade 2000–2010 is to improve the health-related quality of life for people with musculoskeletal conditions throughout the world by raising awareness of the suffering and cost to society associated with these conditions, by empowering patients to participate in decisions concerning their care, by promoting cost-effective prevention and treatment, and by advancing the understanding of musculoskeletal conditions and improving prevention and treatment through research.

Musculoskeletal conditions are extremely common. Osteoarthritis and osteoporosis are particularly prevalent among older people, the number of whom is predicted to increase in all countries, most markedly in developing countries showing an improvement in health outcomes. Disability following road traffic accidents is expected to increase dramatically in developing countries. The question arises as to who will pay for the required medical and social care when, in

many parts of the world, the size of the labour force is declining. There are urgent reasons why, in the words of the United Nations Secretary-General Kofi Annan, we must act now.

This meeting was part of a global health needs assessment, the Bone and Joint Decade Monitor Project, which will provide evidence enabling the development of priorities and strategies to improve the health-related quality of life for people with these conditions, relevant to their geographical and socioeconomic settings. The project aims to:


- identify the current global burden of musculoskeletal conditions;
- estimate its future magnitude;
- establish what can be achieved by effective prevention and treatment;
- establish the present provision of care and the ideal provision of care;
- determine costs and priorities;
- establish methods for monitoring the extent to which the goals are being achieved.

The specific aims of this meeting were to identify, review and compile data on all aspects of the global burden of musculoskeletal conditions, and then to establish widely used outcome measures that could be used to monitor changes in these conditions in all populations. The meeting focused on rheumatoid arthritis, osteoarthritis, osteoporosis, spinal disorders and major limb trauma. The problem of children in each of these categories was taken into consideration. Other conditions, such as gout, fibromyalgia, sprains and strains are important but were not specifically considered. Their burden was partly reflected by much of the information collected in general terms about pain or disability associated with musculoskeletal conditions as a whole. Data were identified and opinions were obtained which were relevant to all geographical and economic situations, providing information for the Global Burden of Disease 2000 Study (GBD 2000).

The measurement of the burden of musculoskeletal conditions (Figure 1) requires a model of the course of the different conditions. It also requires data, or a knowledge of the feasibility of collecting data, on incidence, prevalence and outcome. On the basis of these data, best estimates have to be made of the burdens in question. Summary measures of health which can be used to compare and contrast different conditions and are appropriate to musculoskeletal conditions have to be considered, and a consensus on the assessment of the conditions has to be achieved. Data were identified by a wide network of collaborators in different regions of the world as well as by the members of the Scientific Group. A large proportion of the data



Figure 1  
**Identifying the burden of disease**



WHO 03.102

needed was not readily accessible or was unavailable for certain conditions in some geographical areas. The needs for additional data were identified.

The improvement in health-related outcomes requires the ability to monitor and determine whether and how this is being achieved. For this to be possible it is necessary to reach agreement on indicators and methods of application, the choice of which depends on the condition, the socioeconomic setting and the reason for using the data. In this way we hope to set evidence-based standards, establish priorities and develop methods of observing good practice. By measuring achievements and improving care it is possible to gradually improve the outcomes of people with musculoskeletal conditions, thus reducing the burden on both individuals and society.

Certain key activities undertaken during the Scientific Group Meeting are reported in subsequent chapters.

*Incidence and prevalence*

The available data on the frequency of the index conditions (rheumatoid arthritis, osteoarthritis, osteoporosis, spinal disorders and major limb trauma) and of musculoskeletal conditions in general in different

countries and continents were reviewed. With a view to measuring burden, agreement was reached on the preferred disease definitions for the index conditions. Challenges in interpreting the available data were considered. Gaps in data and the reasons for them were identified. Priorities for collecting additional data or for making estimates on the basis of data obtained in comparable populations were discussed.

#### *Impact on the individual, family and society*

Data were reviewed and expert opinion was sought in relation to the impact on both the individual and society in terms of the health-related quality of life, resource utilization and social consequences. The courses or different stages of the index conditions were discussed, and definitions were agreed for the purpose of identifying burden. Information from different countries and continents on the health and economic impact of the index conditions was reviewed. The reasons for gaps in data were identified. Differences in outcome between geographical and socioeconomic environments were considered, and possible explanations for the differences were examined. This work is continuing.

#### *Measuring the health impact and economic burden of musculoskeletal conditions*

The need for health indicators was considered, and the special requirements in respect of musculoskeletal conditions, particularly the index conditions, were reviewed. Routinely or potentially collected indicators, such as those used for official health statistics, were considered for their relevance to the index musculoskeletal conditions and for their availability in most populations.

The most relevant domains for measuring the different index musculoskeletal conditions were agreed. Methods of describing health status and the consequences of musculoskeletal disorders or injuries were investigated in order to facilitate the development of appropriate summary measures of health. An inventory of assessment instruments for musculoskeletal conditions was developed. Those most suitable for measuring the burden of the index conditions were identified, and their suitability for global application was discussed.

## **2. Global burden of disease**

### **2.1 The Global Burden of Disease Study**

The Global Burden of Disease Study, which began in 1992 (GBD 1990 — based on 1990 data), had three broad goals: to decouple